Form 4: Monopar Therapeutics Director Acquires Stock Options

Director Raymond Anderson acquired 11,365 stock options in Monopar Therapeutics on March 4, 2025.

Summary

• Raymond Anderson, a director of Monopar Therapeutics, acquired 11,365 stock options on March 4, 2025.
• The options have an exercise price of $31.70.
• The options vest 25% quarterly, starting March 31, 2025, and expire on March 4, 2035.
• Following the transaction, Anderson directly owns 11,365 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants. The director's acquisition could be seen as mildly positive, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry to align their interests with those of shareholders.
• The vesting schedule of 25% quarterly is a fairly standard vesting arrangement.
• Comparing the size of this option grant to those of directors at similar-sized biotech companies (e.g., those with market caps between $50 million and $200 million) would provide further context on its significance.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates